{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:06Z","timestamp":1786512486621,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Even in the era of tyrosine kinase inhibitor (TKI) therapy, the prognostic landscape of atypical transcripts in chronic myeloid leukemia (CML) remains poorly defined. In our preliminary work, we identified two atypical transcripts harboring distinct DNA breakpoints that ultimately translate into an identical truncated protein. To investigate the DNA breakpoints of the\n                    <jats:italic>BCR::ABL<\/jats:italic>\n                    fusion gene in two patients with novel e13a3-type CML and to clarify the underlying mechanism of their generation, we conducted a breakpoint analysis. Target DNA fragments were amplified via nested PCR using specific primers, followed by agarose gel purification and sequencing analysis. RT-PCR sequencing identified two distinct e13a3 transcript variants: an 819-bp insertion was detected between BCR exon 13 and ABL exon 3 in patient 1, whereas a 131-bp insertion was found in patient 2. DNA sequencing verified that the breakpoint regions were located in BCR intron 13 and ABL intron 2, which were fully consistent with the cDNA fusion sites. The intronic sequence insertion induced a frameshift, leading to identical premature translation termination at BCR intron 13 in both cases. This resulted in the complete deletion of the entire ABL region, generating a truncated protein with 20-amino acids at the C-terminus of BCR exon 13. This novel e13a3 transcript originates from DNA breakage. Both patients achieved remission after imatinib treatment; molecular docking simulation results show that e13a3 has a lower binding energy with imatinib than e13a2. This finding suggests that in the TKI era, more attention should be paid to the types of truncated proteins resulting from DNA breakpoints.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1932890","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:42:19Z","timestamp":1786509739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Two novel e13a3 variants detected in CML patients and their DNA breakpoint analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Dong","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Blood Transfusion, Peking University First Hospital Taiyuan Hospital (Taiyuan Central Hospital)","place":["Taiyuan, China"]},{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Chang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Xu","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanggang","family":"Ren","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Peking University First Hospital Taiyuan Hospital (Taiyuan Central Hospital)","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Chen","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000330956","article-title":"Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion","volume":"126","author":"Langabeer","year":"2011","journal-title":"Acta Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199807000-00010","article-title":"The molecular biologyof chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v91.2.406","article-title":"The SH3 domain contributes to BCR\/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing","volume":"91","author":"Skorski","year":"1998","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis","volume":"189","author":"Nieborowska-Skorska","year":"1999","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0930","article-title":"CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall","volume":"100","author":"Al-Ali","year":"2002","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11737","article-title":"Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia","volume":"92","author":"Burmeister","year":"2007","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10456","article-title":"Chromic myeloid leukemia with an e13a3 BCR-ABL fusion:benign course responsive to imatinib","volume":"75","author":"Snyder","year":"2004","journal-title":"Am J Hematol"},{"key":"B9","article-title":"Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr\/abl fusion gene","volume":"25","author":"Qin","year":"2004","journal-title":"Chin J Heamotol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0368-4","article-title":"A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement","volume":"90","author":"Masayoshi","year":"2009","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/ol_00000139","article-title":"A rare chronic myeloid leukemia case with Philadelphia chromosome BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes","volume":"1","author":"Al Achkar","year":"2010","journal-title":"Oncol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1155\/2013\/691326","article-title":"Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: the threats and challenges in monitoring minimal residual disease (MRD)","volume":"36","author":"Vaniawala","year":"2013","journal-title":"Anal Cell Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2009.090008","article-title":"A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice","volume":"11","author":"Jinawath","year":"2009","journal-title":"J Mol Diagn"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1151512","article-title":"Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1","volume":"57","author":"Deshpande","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107733","article-title":"Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts","volume":"155","author":"Wang","year":"2025","journal-title":"Leukemia Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03569-8","article-title":"Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network","volume":"147","author":"Sch\u00e4fer","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2017.05.009","article-title":"A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)","volume":"59","author":"Duan","year":"2017","journal-title":"Leuk Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.4826","article-title":"Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Med Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13548","article-title":"Efficacy of dasatinib in a very elderly CML patient expressing a rare E13a3 bcr-abl1 fusion transcript: A case report","volume":"39","author":"Massimino","year":"2019","journal-title":"Anticancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2014.03.007","article-title":"A clinical and laboratory study of chronic myeloid leukemia with atypical BCR- ABL fusion gene subtypes","volume":"35","author":"Gui","year":"2014","journal-title":"Chin J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2017.04.010","article-title":"Application of real-time quantitative PCR in detecting atypicalBCR\/ABLmRNA transcripts in chronic myelocytic leukemia","volume":"25","author":"Zou","year":"2017","journal-title":"J Exp Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergencyto.2010.03.017","article-title":"A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study","volume":"201","author":"Sadia","year":"2010","journal-title":"Cancer Genet Cytogenetics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3892\/ol.2025.15065","article-title":"Chronic myeloid leukemia with the e13a3 atypical fusion gene: A case report","volume":"29","author":"Zhou","year":"2025","journal-title":"Oncol Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0452-3","article-title":"Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion","volume":"32","author":"McCarron","year":"2015","journal-title":"Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10429","article-title":"Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3","volume":"74","author":"Liu","year":"2003","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1622101","article-title":"Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1","volume":"60","author":"Xua","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/sajc.sajc15818","article-title":"Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR\u2013ABL1: A report of four cases from India","volume":"8","author":"Sazawal","year":"2019","journal-title":"South Asian J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3892\/or.2025.8995","article-title":"The silent players: Atypical BCR-ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review)","volume":"54","author":"Zhou","year":"2025","journal-title":"Oncol Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.3.287","article-title":"Chronic myeloid leukemia with rare variant b2a3 (e13a3) BCR-ABL1 fusion","volume":"36","author":"Ha","year":"2016","journal-title":"Ann Lab Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:42:28Z","timestamp":1786509748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1932890"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1932890","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1932890"}}